ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q4 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brett A. Sandercock - Chief Financial Officer Michael J.
Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.08 per share a year ago.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ResMed: A Sleeping Giant Hiding In Plain Sight
ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's sticky, essential products and expanding digital platform create a powerful, recession-resistant business model with strong secular tailwinds. We forecast 10% compound annual growth through 2030, with shares offering 13-21% upside based on reasonable valuation multiples and robust earnings growth.
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
